<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0587248" disease_type="Disease or Syndrome" abbrv="">Costello syndrome</z:e> (CS) is a rare <z:e sem="disease" ids="C0242354" disease_type="Disease or Syndrome" abbrv="">congenital disorder</z:e> characterized by <z:hpo ids='HP_0001525'>severe failure to thrive</z:hpo>, coarse facial appearance, cardiac and <z:mp ids='MP_0002096'>skin abnormalities</z:mp>, <z:hpo ids='HP_0001263'>developmental delay</z:hpo>, <z:hpo ids='HP_0001249'>intellectual disability</z:hpo>, and predisposition to <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Heterozygous de novo germline mutations in the proto-oncogene HRAS cause CS </plain></SENT>
<SENT sid="2" pm="."><plain>About 80% of patients share the same mutation resulting in the amino acid change p.G12S and present a relatively homogeneous phenotype </plain></SENT>
<SENT sid="3" pm="."><plain>Other less common lesions in HRAS can induce a milder phenotype on the one hand and a more severe phenotype on the other broadening the spectrum of clinical manifestations in CS-affected individuals </plain></SENT>
<SENT sid="4" pm="."><plain>We report two new patients with the HRAS p.G12C and p.G12D substitutions and a severe neonatal manifestation causing <z:hpo ids='HP_0011420'>death</z:hpo> at the age of three months and 13 days, respectively </plain></SENT>
<SENT sid="5" pm="."><plain>Both patients had particularly severe heart involvement with <z:hpo ids='HP_0001639'>hypertrophic cardiomyopathy</z:hpo> and tachyarrhythmia, <z:hpo ids='HP_0007430'>generalized edema</z:hpo>, and <z:hpo ids='HP_0002098'>respiratory distress</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>In one case, <z:hpo ids='HP_0001639'>hypertrophic cardiomyopathy</z:hpo> was already noted prenatally </plain></SENT>
<SENT sid="7" pm="."><plain>These cases together with other individuals harboring the rare HRAS mutations p.G12C, p.G12V, p.G12D, and p.G12E provide further evidence for a genotype-phenotype correlation that could be of importance for counseling and medical management </plain></SENT>
</text></document>